360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Lovaza

Type: Product

Name: Lovaza

First reported May 20 2013 - Updated May 21 2013 - 1 reports

GlaxoSmithKline plc

Vascepa Data Should Make Amarin Longs Worried

Amarin (AMRN) had been trading bullish on the heels of their quarterly conference call two weeks ago where they reported a continued increase in Vascepa sales and $2.3 million in recognized Vascepa revenues. Amarin made a 20% run after earnings, but has ... [Published Seeking Alpha - May 20 2013]

Entities: Amarin Corporation Plc, Lovaza, Polyunsaturated Fat, Therapeutics, GlaxoSmithKline plc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

FDA Food & Drug Administration

Amarin: It's The Strategy, Not The Science

Talk about betting the entire ship on fish oil.New Jersey's Amarin Corporation (NASDAQ: AMRN) braves the global biopharmaceutical industry with only one product: Vascepa (codenamed AMR-101), a prescription grade omega-3 fatty acid drug for cardiovascular ... [Published Seeking Alpha - May 20 2013]

Entities: Amarin Corporation Plc, Lovaza, Triglycerides, FDA Food & Drug Administration, Omega-3 Fatty Acid

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Amarin Corporation plc (ADR) (AMRN) & More: Who?s Being Tested?

A study published in The New England Journal of Medicine testing omega-3 fatty acids -- commonly found in fish oil -- in patients with risk factors for cardiovascular disease came up with a pretty wishy-washy conclusion. The take-home message from the ... [Published InsiderMonkey.com - May 13 2013]

Entities: Triglycerides, Amarin Corporation Plc, Omega-3 Fatty Acid, FATTY ACIDS

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Amarin Corporation Plc

Italian OTC Fish Oil Study Has No Bearing On Vascepa Outcomes

The erroneous coverage by various media outlets and Street.com slime-ball Adam Fuerstein attempts to relate a poorly designed Italian OTC fish oil study with outcomes for Omega-3 class Rx drugs. WRONG GUYS...Let me ask a question. If you had a headache ... [Published Seeking Alpha - May 10 2013]

Entities: Lovaza, Aegis Capital, Amarin Corporation Plc, Tylenol

First reported May 07 2013 - Updated May 08 2013 - 2 reports

Pivotal Therapeutics says Vascazen product can correct Omega-3 deficiency in patients with heart disease

Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease (CVD), revealed today results from its Vascazen "Reveal" clinical trial, saying the product was "highly effective" ... [Published Proactiveinvestors United Kingdom website - May 07 2013]

Entities: Omega-3 Fatty Acid, Triglycerides, Pivotal Therapeutics Inc

First reported May 07 2013 - Updated May 07 2013 - 1 reports

BASF SE

Amarin gets BASF approved to make Vascepa

Amarin ($AMRN) has been setting up a global network of contractors for manufacturing its fish oil product Vascepa so it is ready to go when it starts its hard push for the heart drug. It says today that it has forged two more links in the chain of manufacturing ... [Published FiercePharma - May 07 2013]

Entities: BASF SE, Amarin Corporation Plc, Pronova BioPharma ASA, Omega-3 Fatty Acid

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Pivotal Therapeutics narrows losses on first sales of Vascazen as product build-up continues

Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a pharmaceutical company focused on Omega-3 therapies for cardiovascular disease, has unveiled its year-end results, narrowing its loss from a year earlier as sales increased and expenses were reduced.For ... [Published Proactive Investors USA - Apr 30 2013]

Entities: Pivotal Therapeutics Inc, Omega-3 Fatty Acid, Lovaza, Docosahexaenoic Acid

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Amarin: The Bull Argument (Or How I Learned To Stop Worrying And Love Vascepa)

ByBond Wells: The bull argument for Amarin's ( AMRN ) Vascepa is simple: it works better than Lovaza, it doesn't have the negative aspects, it doesn't have an atrial fibrillation warning, it is applying for (and should receive) approval to be marketed ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 30 2013]

Entities: Amarin Corporation Plc, Lovaza, Atrial Fibrillation

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

No CV, mortality benefit with omega-3 fatty acids in diabetes patients

Level 1: Likely reliable evidenceEvidence for the effect of omega-3 fatty acids on cardiovascular (CV) risk has been inconsistent. While some systematic reviews have found little or no evidence that dietary or supplementary omega-3 fatty acid intake alters ... [Published The Clinical Advisor - Apr 30 2013]

Entities: Omega-3 Fatty Acid, FATTY ACIDS, Mortality

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

GSK eyes windfall from Lucozade and Ribena sell-offs

GlaxoSmithKline's financials for the first quarter have been overshadowed by the news that it is selling Lucozade and Ribena in a move that could net the UK drugs giant in excess of £1 billion.Turnover fell 2% to £6.47 billion, while core operating profit ... [Published Pharma Times - Apr 25 2013]

Entities: Ribena, Lucozade, Chronic Obstructive Pulmonary Disease, Drugs, Simon Dingemans

First reported Apr 23 2013 - Updated Apr 23 2013 - 2 reports

Pivotal Therapeutic’s Omega-3 Vascazen product: the way to the heart

For years, we have been told that Omega 3s can help boost health. But some of us may need more than a little fish to make the difference. Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO) has an U.S. regulated Omega 3 prescription product on its hands ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 23 2013]

Entities: Omega-3 Fatty Acid, Docosahexaenoic Acid, Triglycerides

First reported Apr 15 2013 - Updated Apr 16 2013 - 1 reports

No NCE for Amarin’s Vascepa, Launch Trudges Along

It was another month, and another non-decision on the NCE status of Amarin Corporation’s (NASDAQ: AMRN) Vascepa (icosapent ethyl), which is an unsurprising but significant short-term blow to investor sentiment. This was reflected quite well with the price ... [Published BioMedReports - Apr 15 2013]

Entities: Amarin Corporation Plc, Lovaza, Omega-3 Fatty Acid, Earnings Report

Quotes

...to make its next move up or down which will be catalyzed by prescription data, guidance and the company's ANCHOR indication: From its website, "Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription." It's become noted many times over that Amarin's handling of its launch of Vascepa is ultimately going to determine the path the company is going to take...

Vascepa Data Should Make Amarin Longs Worried [Published Seeking Alpha - May 20 2013]

"The data from the publication and those presented at ESC suggest that pure EPA therapy not reduces triglyceride levels, but also improves additional non-lipid parameters" says Amarin CEO Joseph Zarkrzewski

Amarin: It's The Strategy, Not The Science [Published Seeking Alpha - May 20 2013]

...One gram isn't a whole lot. The recommended dose for GlaxoSmithKline plc (ADR) (NYSE:GSK) "s prescription-grade fish oil Lovaza is 4 grams. Ditto for Amarin Corporation plc (ADR) (NASDAQ:AMRN)" s Vascepa. Omthera Pharmaceuticals Inc (NASDAQ:OMTH)'s has seen good results with a 2-gram dose of its omega-3 drug Omthera Pharmaceuticals Inc (NAS...

Amarin Corporation plc (ADR) (AMRN) & More: Who?s Being Tested? [Published InsiderMonkey.com - May 13 2013]

"The statistically significant elevation in Omega-3 levels, drop in triglycerides, and the elevation of HDL cholesterol, all in eight weeks, evidences the deficiency is being corrected and patients are seeing results."

Pivotal Therapeutics says Vascazen product can correct Omega-3 deficiency in patients with heart ... [Published Proactiveinvestors United Kingdom website - May 07 2013]

More Content

sort by: Date \| Relevance
Vascepa Data Should Make Amarin Longs Worried [Published Seeking Alpha - May 20 2013]
Amarin: It's The Strategy, Not The Science [Published Seeking Alpha - May 20 2013]
Amarin Corporation plc (ADR) (AMRN) & More: Who... [Published InsiderMonkey.com - May 13 2013]
Amarin Reports Solid Vascepa TRx Growth, Stock ... [Published BioMedReports - May 13 2013]
New Market Report Now Available: Pronova BioPha... [Published PR inside - May 12 2013]
Omthera Pharmaceuticals Receives New Coverage f... [Published American Banking News - May 12 2013]
Some Fish Oil Doesn't Help Some Patients in Som... [Published Motley Fool - May 11 2013]
Another Negative Fish Oil Study Adds To Amarin'... [Published Investopedia - May 11 2013]
Italian OTC Fish Oil Study Has No Bearing On Va... [Published Seeking Alpha - May 10 2013]
Pivotal Therapeutics says Vascazen product can ... [Published Proactiveinvestors United Kingdom website - May 07 2013]
Amarin gets BASF approved to make Vascepa [Published FiercePharma - May 07 2013]
Pivotal Therapeutics says Vascazen product can ... [Published Proactive Investors USA - May 07 2013]
UPDATE: Piper Jaffray Initiates Omthera Pharmac... [Published Benzinga.com - May 07 2013]
Amarin: The Bull Argument (Or How I Learned To ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 30 2013]
Pivotal Therapeutics narrows losses on first sa... [Published Proactive Investors USA - Apr 30 2013]
No CV, mortality benefit with omega-3 fatty aci... [Published The Clinical Advisor - Apr 30 2013]
GSK eyes windfall from Lucozade and Ribena sell... [Published Pharma Times - Apr 25 2013]
Pivotal Therapeutic’s Omega-3 Vascazen product:... [Published Proactiveinvestors United Kingdom RSS feed - Apr 23 2013]
Pivotal Therapeutic’s Omega-3 Vascazen product:... [Published Proactive Investors USA - Apr 23 2013]
Amarin's Fish Oil Pill Faces Even More Exclusiv... [Published TheStreet.com - Apr 22 2013]
Fish Oil: Drugs vs. Supplements [Published Natural Products Industry Insider - Apr 19 2013]
My 5 Summer Stock Market Flings For 2013 [Published Seeking Alpha - Apr 19 2013]
US IPO Recap: Six deals price in another strong... [Published Nasdaq - Apr 15 2013]
No NCE for Amarin’s Vascepa, Launch Trudges Along [Published BioMedReports - Apr 15 2013]
AAFP CME Program Succumbs to “Integrative Medic... [Published Science-Based Medicine - Apr 02 2013]
Drug Patent Expirations for Mar 26 2013 [Published Biotech Blog - Mar 26 2013]
Drug Patent Expirations in March 2013 [Published Biotech Blog - Mar 01 2013]
Amarin's Vascepa: 5 Myths Debunked [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 25 2013]
What Will FDA Tell Amarin About Its Fish Oil Pill? [Published Pharmalot - Dec 14 2012]
Financings of the Fortnight Comes Bearing Gifts [Published The IN VIVO Blog - Dec 14 2012]

Blogs

sort by: Date \| Relevance
Pivotal Therapeutics says Vascazen product can ... [Published Proactiveinvestors United Kingdom website - May 07 2013] Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease (CVD), revealed today results from its Vascazen "Reveal" clinical trial, saying the product was "highly effective" ...
AAFP CME Program Succumbs to “Integrative Medic... [Published Science-Based Medicine - Apr 02 2013] For many years I have been using Continuing Medical Education (CME) programs offered by the American Academy of Family Physicians (AAFP). The FP Essentials program consists of a monthly monograph with a post-test that can be submitted electronically ...
Drug Patent Expirations for Mar 26 2013 [Published Biotech Blog - Mar 26 2013] Copyright © thinkBiotech If your reader cannot render the information below, go tohttp://www.DrugPatentWatch.com/innovation to see the latest expirationsbody { font-family:Calibri, tahoma, arial,sans-serif;}table { font-size:12px; font-family:Calibri, ...
Drug Patent Expirations in March 2013 [Published Biotech Blog - Mar 01 2013] Copyright © thinkBiotech Drug Patent Expirations for March 2013TradenameApplicantGeneric NamePatent NumberPatent Expiration THALOMID Celgene thalidomide 8,143,283 Mar 1, 2013 THALOMID Celgene thalidomide 7,723,361 Mar 1, 2013 THALOMID Celgene ...
What Will FDA Tell Amarin About Its Fish Oil Pill? [Published Pharmalot - Dec 14 2012] Today may be a turning point in one of the more captivating stock stories to unfold in the pharmaceutical industry this year. Why? The FDA may finally issue a decision on whether to grant new molecular entity status to Vascepa, a fish oil pill sold ...